Bio Green Med Solution, Inc. (BGMS): Nasdaq/NYSE listing notice — Cyclacel gets 180-day Nasdaq extension to Jan 2, 2024 to regain $1.00 bid price compliance

Bio Green Med Solution, Inc.

Received extension on July 5, 2023; must comply by January 2, 2024.
Previously disclosed non-compliance on Jan 6, 2023; original cure period ended July 3, 2023.
Company intends to cure via reverse stock split if necessary, within ten business days before extension expires.
If not cured by Jan 2, 2024, Nasdaq will issue delisting notice; Company may appeal to Hearing Panel.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Bio Green Med Solution, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

July 5, 2023, Cyclacel Pharmaceuticals, Inc. (the “ Company ”) received a letter (the “ Extension Notice ”) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) notifying the Company that Nasdaq has granted the Company a 180-day extension, or until January 2, 2024 (the “ Extension Period ”), to regain compliance with the requirement for the Company’s common stock, par value $0.001 per share (“ Common Stock ”), to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “

View on SEC.gov

Browse all listing & compliance notices →

Bio Green Med Solution, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-079107

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.